Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Pontes, Caridad ^a   Gratacós, Jordi ^a   Torres, Ferran ^b   Avendaño, Cristina ^c   Sanz, Jesús ^c   Vallano, Antoni ^d   Juanola, Xavier ^d   Miguel, Eugenio ^e   Sanmartí, Raimon ^f   Calvo, Gonzalo ^f  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Disease Activity; DMARDs (biologic); Spondyloarthritis therapy; Treatment

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPONDYLARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BIOMECHANICS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONVALESCENCE; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; METHODOLOGY; PATHOPHYSIOLOGY; SPAIN; SPINE; TIME FACTOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; BIOMECHANICAL PHENOMENA; CLINICAL PROTOCOLS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REMISSION INDUCTION; RESEARCH DESIGN; SPAIN; SPINE; SPONDYLARTHRITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940046999     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0828-5     Document Type: Article

References (56)

1. Dougados M, Van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum. 1991;34:1218-27.
2. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8.
3. Rudwaleit M, Landewe R, Van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770-6.
4. Rudwaleit M, Van der Heijde D, Landewé R. New ASAS classification criteria for peripheral spondyloarthritis. Ann Rheum Dis. 2009; 2:OP-0168.
5. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondyloarthritis in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58-67.
6. Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum. 1993;22:319-34.
7. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S16-22.
8. Rojas-Vargas M, Munoz-Gomariz E, Escudero A, Font P, Zarco P, Almodovar R, et al. First signs and symptoms of spondyloarthritis -data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology (Oxford). 2009;48:404-9.
9. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014;11:CD004800. doi: 10.1002/14651858.CD004800 .
10. Grupo ESPOGUIA. Guía de práctica clínica sobre el manejo de los pacientes con Espondiloartritis. Madrid: Sociedad Española de Reumatología; 2009.
11. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42:2325-9.
12. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756-65.
13. Van der Heijde D, Maksymowych WP. Spondyloarthritis: state of the art and future perspectives. Ann Rheum Dis. 2010;69:949-54.
14. Coates LC, Cawkwell LS, Bennett NWFNAN, Bryer DJ, Fraser AD, Emery P, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology. 2008;47:897-900.
15. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
16. Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev. 2011;10:563-8.
17. Busquets N, Carmona L, Surís X. Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos. Reumatol Clin. 2011;7:104-12.
18. Baraliakos X, Listing J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005; 7):R439-44.
19. Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005;44:342-8.
20. Torrente V, Gratacos J, Juanola X, Sanmarti R, Suarez D, Moreno M, et al. Infliximab Withdrawal in Patients with Spondyloarthritis Who Presented Criteria of Clinical Disease Remission. An Open Study of Clinical Practise (REMINEA) [abstract]. Arthritis Rheum. 2009;60:1785.
21. Navarro-Compán V, Moreira V, Ariza-Ariza R, Hernández-Cruz B, Vargas-Lebrón C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30:993-6.
22. Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:1203-10.
23. Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, et al. Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatology (Oxford). 2006;45:1566-9.
24. Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol. 2006;33:558-61.
25. González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200-9.
26. Reveille JD, Ximenes A, Ward MM. Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci. 2012;343:371-4. doi: 10.1097/MAJ.0b013e3182514093 . PubMed.
27. Juanola X, Zarco P, Sanz J, Muñoz S, Mulero J, Linares LF, et al. Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica. Reumatol Clin. 2011;7:113-23.
28. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005;64:1462-6.
29. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004;50:2622-32.
30. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393-7.
31. Janet D. Elashoff (2005) nQuery Advisor Version 6.01. Statistical Solutions, Cork, eland. URL: http://www.statsol.ie/index.php?pageID = 2. Accessed July 16 2015.
32. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1988;17:873-90.
33. CPMP/ICH/363/96. ICH E9 Statistical Principles for Clinical Trials. URL: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500002928 . Accessed July 16 2015.
34. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162:199-200.
35. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123:174-84.
36. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160:301-5.
37. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability Vol 1. Berkeley, CA: University of California Press; 1967. p. 221-33.
38. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
39. Verbeke G, Molenberghs G. Linear Mixed Models for longitudinal Data. New York: Springer-Verlag; 2000.
40. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley; 1973.
41. Hodges JL, Lehmann EL. Estimates of location based on rank tests. Annals Mathematical Stat. 1963;34:598-611.
42. Brown H, Prescott R. Applied Mixed Models in Medicine. New York: J. Wiley & Sons; 1999.
43. Molenberghs G, Kenward MG. Missing data in clinical Studies. Chichester, West Susex: John Wiley & Sons, Ltd.; 2007.
44. ICH Topic E 6 (R1): Note for guidance on good clinical practice. CPMP/ICH/135/95. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf . Accessed July 16 2015.
45. CHMP. Points to Consider on Switching between Superiority and Non-Inferiority (CPMP/EWP/482/99). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf . Accessed July 16 2015.
46. Mantel N, Haenszel W. Statistical aspects of the analysis of data of retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
47. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665.
48. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801.
49. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-91.
50. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18-24.
51. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-5.
52. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83.
53. European Medicines Agency. Humira: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf . Accessed July 16 2015.
54. European Medicines Agency. Enbrel: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf . Accessed July 16 2015.
55. European Medicines Agency. Simponi: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf . Accessed July 16 2015.
56. European Medicines Agency. Remicade: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf . Accessed July 16 2015.